NCT01843374 · OUTCOME

Number of Participants Reporting Any Adverse Event

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma · Source last updated 2026-07-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Participants
Interval / dispersion: Not reported
Time frame: Day 1- 90 days post dose

What was measured

Any untoward medical occurrence in a patient or clinical investigation participants administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

Analysis population: Safety population

Groups in this outcome

TREMELIMUMAB

Tremelimumab 10mg/kg

PLACEBO

Placebo.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
TREMELIMUMAB	380
PLACEBO	189

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
TREMELIMUMAB	364	Not reported	Not reported	Not reported	Not reported
PLACEBO	179	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
364
group Id
OG001
value
179

denom Units Selected

Participants

denoms

counts
group Id
OG000
value
380
group Id
OG001
value
189
units
Participants

description

groups

description
Tremelimumab 10mg/kg
id
OG000
title
TREMELIMUMAB
description
Placebo.
id
OG001
title
PLACEBO

param Type

NUMBER

population Description

Safety population

reporting Status

POSTED

time Frame

Day 1- 90 days post dose

title

Number of Participants Reporting Any Adverse Event

type

SECONDARY

type Units Analyzed

Participants

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice